09:50 AM EDT, 10/31/2024 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) shares were rising past 11% in recent Thursday trading after the company reported a Q3 loss of $4.92 per diluted share, narrower than its loss of $5.34 a year earlier.

Analysts polled by Capital IQ expected a loss of $6.92.

Revenue for the quarter ended Sept. 30 was $62.2 million. The company said no product sales were recognized in the comparable year earlier period.

Analysts surveyed by Capital IQ expected $34.4 million.

Price: 240.55, Change: +24.62, Percent Change: +11.40